Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

If Fallout were a person, it would be that slightly eccentric friend who can talk for hours about the 1950s - but also knows way too much about nuclear war, mutant wildlife, and improvised survival re ...